Table 1.
Clinical characteristics of patients studied.
| Characteristics n (%) | Obstetric seronegative anti-phospholipid syndrome (OSN-APS) (total) (n = 61) | OSN-APS (followed up) (n = 35) |
|---|---|---|
| Other autoimmune diseases | ||
| Systemic lupus erythematosus | 7 (11.5) | 5 (14.3) |
| Discoid lupus erythematosus | 5 (8.2) | 5 (14.3) |
| Autoimmune thyroiditis | 11 (18.0) | 10 (28.6) |
| Mixed connective tissue disease | 3 (4.9) | 1 (2.8) |
| Undifferentiated connective tissue disease | 2 (3.3) | 1 (28) |
| Pregnancy morbidity | ||
| Spontaneous abortionsa | 41 (67.2) | 25 (71.4) |
| Intrauterine death of a normal fetusb | 27 (44.3) | 15 (42.9) |
| Premature birthsc | 4 (6.6) | 2 (5.7) |
| Vascular thrombosisd | 9 (14.6) | 6 (17.1) |
| Arterial thrombosis | 4 (6.6) | 3 (8.6) |
| Venous thrombosis | 6 (9.8) | 4 (11.4) |
| Recurrent thrombosis | 4 (6.6) | 3 (8.6) |
| Non-criteria APS features | ||
| Livedo reticularis | 11 (18.0) | 8 (22.9) |
| Thrombocytopenia | 4 (6.6) | 4 (11.4) |
| Migraine | 9 (14.6) | 5 (14.3) |
| Seizures | 1 (1.6) | 1 (2.9) |
| Thrombotic risk factors | ||
| Hypercholesterolemia | 3 (4.9) | 3 (8.5) |
| Smoking | 10 (16.4) | 7 (20.0) |
| Hypertension | 7 (11.5) | 6 (17.1) |
| Oral contraceptive/hormone replacement therapy | 1 (1.6) | 0 (0) |
a3 or + losses <10 weeks of gestation.
b1 or + losses ≥10 weeks of gestation.
cPreterm birth <34 weeks due to eclampsia, pre-eclampsia, or placental insufficiency.
dThrombosis (arterial, venous, or in small vessels) in any tissue, confirmed by imaging or histopathology (thrombosis without significant inflammation).